Erlotinib for metastatic non-small-cell lung cancer: First-, second- or third-line setting - Does it matter? A single-institution experience

Oncology

Volumn 76, Issue 2, 2009, Pages 85-90

  Ailawadhi, Sikander ^a   Derby, Lyudmyla ^b   Natarajan, Raj ^c   Fetterly, Gerald ^c   Reid, Mary ^c   Ramnath, Nithya ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Erlotinib; Metastatic non small cell lung cancer; Non small cell lung cancer; Tarceva

Indexed keywords

ERLOTINIB;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DRUG WITHDRAWAL; FEMALE; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SMOKING; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES;

EID: 58149099349     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000187427     Document Type: Article

References (21)

1. Travis WD, Lubin J, Ries L, Devesa S: United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996;77:2464-2470.
2. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
3. Pisani P, Parkin DM, Ferlay J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55:891-903.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA 2007;57:43-66.
5. Ries LAG, Krapcho M, et al: SEER cancer statistics review, 1975-2004, National Cancer Institute. Bethesda, MD, based on November 2006 SEER data submission, 2007.
6. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA 2003;53:5-26.
7. Linnoila RI, Aisner SC, et al: Pathology of lung cancer: an exercise in classification; in Johnson BE, Johnson DH (eds): Lung Cancer. New York, Wiley-Liss, 1995.
8. Bunn PA Jr: Treatment of advanced nonsmall-cell lung cancer with two-drug combinations. J Clin Oncol 2002;20:3565-3567.
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
10. Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20:1S-13S.
11. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11:6414-6421.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
13. Hann CL, Brahmer JR: Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when? Curr Treat Options Oncol 2007;8:28-37.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
15. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
16. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Janne PA: Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-766.
17. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, Janne P, Oulid-Aissa D, Soria JC: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006;12:6049-6055.
18. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH: Clinical model to predict survival in chemonaive patients with advanced nonsmall-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005;23:175-183.
19. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279.
20. Tarceva (erlotinib) tablets, OSI Pharmaceuticals Inc, 2004.
21. Sequist LV, Joshi VA, Janne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ: Response to treatment and survival of patients with nonsmall cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007;12:90-98.